Related Experiment Videos
Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study
Kenneth J Warrington1, Elena P Jarpa, Cynthia S Crowson
1Department of Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA. warrington.kenneth@mayo.edu
Introduction:
The present study was conducted to determine whether patients with polymyalgia rheumatica (PMR) are at an increased risk of peripheral arterial disease (PAD).
Methods:
An inception cohort of all Olmsted County, Minnesota residents diagnosed with PMR between 1 January 1970 and 31 December 1999 was compared with non-PMR subjects (two for each PMR subject) from among residents. Both cohorts were followed longitudinally by complete medical record review from the incidence date of PMR (or index date for the non-PMR cohort) until death, incident PAD, migration, or 31 December 2006. PMR-related disease characteristics, traditional cardiovascular risk factors and diagnosis of PAD were abstracted from the medical record. Cumulative incidence of PAD was estimated using Kaplan-Meier methods. Cox proportional hazards models were used to assess the risk of PAD in PMR compared with non-PMR.
Results:
A total of 353 PMR patients (mean age 73.3 years, 67% women) and 705 non-PMR subjects (mean age 73.2 years, 68% female) were followed for a median of 11.0 years. PAD developed in 38 patients (10-year cumulative incidence, 8.5%) with PMR and in 28 non-PMR subjects (10-year cumulative incidence, 4.1%) (hazard ratio (95% confidence interval), 2.40 (1.47, 3.92)). After adjusting for traditional cardiovascular risk factors, patients with PMR still had a significantly higher risk for PAD (hazard ratio, 2.50 (1.53, 4.08)) compared with controls. Giant cell arteritis occurred in 63 (18%) PMR patients but was not predictive of PAD (P = 0.15). There was no difference between mortality in PMR and the non-PMR cohorts nor in PMR patients with and those without PAD (P = 0.16).
Conclusions:
Patients with PMR appear to have an increased risk of PAD.
Insights
Patients with polymyalgia rheumatica (PMR) have a significantly higher risk of developing peripheral arterial disease (PAD). This study confirms an increased PAD risk in PMR patients, even after accounting for other cardiovascular factors.
Area of Science:
- Rheumatology
- Cardiovascular Medicine
- Epidemiology
Background:
- Polymyalgia rheumatica (PMR) is an inflammatory condition.
- The association between PMR and peripheral arterial disease (PAD) requires further investigation.
Purpose of the Study:
- To determine if patients diagnosed with polymyalgia rheumatica (PMR) face an elevated risk of peripheral arterial disease (PAD).
Main Methods:
- An inception cohort of PMR patients from Olmsted County, Minnesota, was compared to a control group.
- Longitudinal follow-up via medical record review was conducted from diagnosis until 2006.
- Cox proportional hazards models were employed to assess PAD risk in PMR patients versus controls.
Main Results:
- Patients with PMR showed a significantly higher cumulative incidence of PAD compared to non-PMR subjects.
- The adjusted hazard ratio for PAD in PMR patients was 2.50 (1.53, 4.08), indicating a 2.5-fold increased risk.
- Giant cell arteritis, a related condition, did not predict PAD development in PMR patients.
Conclusions:
- Polymyalgia rheumatica (PMR) is associated with an increased risk of peripheral arterial disease (PAD).
- This finding highlights the importance of cardiovascular risk assessment in PMR patients.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Peripheral Artery Disease IV: Nursing Management
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...